Cue Biopharma (CUE) to Release Earnings on Monday

Cue Biopharma (NASDAQ:CUE) is projected to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $1.00 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 16, 2026 at 7:00 AM ET.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings data on Monday, March 16th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $21.94 million for the quarter. Cue Biopharma had a negative net margin of 96.85% and a negative return on equity of 165.19%. On average, analysts expect Cue Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cue Biopharma Price Performance

Shares of CUE stock opened at $0.24 on Friday. The business has a fifty day moving average of $0.31 and a 200 day moving average of $0.49. Cue Biopharma has a 1 year low of $0.22 and a 1 year high of $1.05. The firm has a market capitalization of $23.29 million, a price-to-earnings ratio of -0.75 and a beta of 1.51.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cue Biopharma in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On Cue Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in CUE. Stifel Financial Corp increased its holdings in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after purchasing an additional 50,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after buying an additional 73,000 shares during the period. Squarepoint Ops LLC acquired a new stake in Cue Biopharma during the third quarter valued at $62,000. Finally, Boothbay Fund Management LLC increased its holdings in Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after buying an additional 93,333 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.